

Formerly known as Shanmuga Hospital Private Limited

Reg. Off: 51/24, Saradha College Road, Salem—636 007.
CIN: L85110TZ2020PLC033974 | GSTIN: 33ABDCS8326A1ZP
Tele: 0427-2706674 |E-mail: secretarial@shanmugahospital.com
Website: www.shanmugahospital.com

ISIN: INEOTD301017 | Symbol: SHANMUGA |Script Code: 544365

SHL/SE/2025-26/44

12/11/2025

To
The Listing Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai-40000, Maharashtra
Scrip Code: 544365 | ISIN: INEOTD301017

Sub: Outcome of Board meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015. We wish to inform you that meeting of the Board of Directors of the Company held today i.e., Wednesday, 12<sup>th</sup> November, 2025 at Registered Office which commenced at 03:00 P.M. (IST) and concluded at 04:25 P.M. (IST) has taken inter-alia consider and approve the Un-Audited Financial Results of the company for the Half year ended 30<sup>th</sup> September 2025, as reviewed and recommended by Audit Committee at its meeting held today.

Results are available in Company website <a href="https://shanmugahospital.com/investor-relations/">https://shanmugahospital.com/investor-relations/</a>

The Un-audited financial results along with the Limited Review Report are enclosed.

You are requested to kindly take the above information on your record.

Thanking you,

For Shanmuga Hospital Limited

# CS K Anjana Maragatham

Company Secretary & Compliance Officer M. No: A70080









# PPNAND COMPANY CHARTERED ACCOUNTANTS

No.2, IV Cross Street, Sterling Road, Nungambakkam, Chennai - 600 034. (Near to Loyola College) Ph: 044-2828 0033, Cell: 98844 48912.

E-mail: info@ppnaco.com | Web: www.ppnaco.com | www.ppnaco.co.in

Independent Auditor's Limited Review Report on unaudited standalone financial results of Shanmuga Hospital Limited (formerly known as Shanmuga Hospital Private Limited) for the half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

The Board of Directors, Shanmuga Hospital Limited (formerly known as Shanmuga Hospital Private Limited)

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of M/s Shanmuga Hospital Limited (formerly known as Shanmuga Hospital Private Limited) (the "Company"), which comprise the Balance Sheet as at September 30, 2025, and the Statement of Profit and Loss and Cash Flow Statement for the period ended September 30, 2025, ("the statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulation").
- 2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standards (AS' 25) "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the financial statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance about whether the Statement is free from material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all



significant matters that might be identified in an audit. Thus, we have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 as amended, read with rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

ND CO

CHENNA

600 034

For PPN and Company

**Chartered Accountants** 

Firm's Registration No: 013623S Peer review Certificate No. 020690

R. Rajaram Partner

Membership No.: 238452

UDIN: 25238452BMHSXH9020

Date: 12-11-2025 Place: Chennai

# (formerly known as Shanmuga Hospital Private Limited) CIN: L85110TZ2020PLC033974

51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

## Statements of Assets & Liabilities as at September 30, 2025

(All amounts are in ₹. lakhs unless stated)

As at September 30, A					
Sr	Dandanlan	(Unaudited)	As at March 31,		
Sr	Particulars	_ ` '	(Audited)		
		2025	2025		
I.	EQUITY AND LIABILITIES				
1	SHAREHOLDERS' FUNDS				
	(a) Share Capital	1,361.30	1,361.30		
	(b) Reserves and Surplus	2,809.63	2,608.50		
2	NON-CURRENT LIABILITIES				
	(a) Long-Term Borrowings	359.35	359.35		
	(b) Deferred Tax Liabilities (Net)	68.86	41.35		
	(c) Long-Term Provisions	-	11.04		
3	CURRENT LIABILITIES				
	(a) Short-Term Borrowings	379.02	402.10		
	(b) Trade Payables				
	(i) Total outstanding dues of Micro Enterprises and Small				
	Enterprises and	14.45	12.11		
	(ii) Total outstanding dues of creditors other than Micro	412.26	266.05		
	Enterprises and Small Enterprises	413.26	366.05		
	(c) Other Current Liabilities	43.47	115.59		
	(d) Short-Term Provisions	-	0.72		
	TOTAL EQUITY AND LIABILITIES	5,449.34	5,278.10		
II.	ASSETS				
1	NON-CURRENT ASSETS				
1	(a) Property, Plant & Equipment and Intangible Assets				
	(i) Property, Plant & Equipment and Intanglote Assets	3,762.57	2,242.71		
	(i) Capital Work-in-Progress	178.78	2,242./1		
	. , , ,	2.74	2.74		
			2.74		
	(c) Other Non-Current Assets	142.62	31.64		
2	CURRENT ASSETS				
	(a) Inventories	297.97	288.97		
	(b) Trade Receivables	620.71	796.05		
	(c) Cash & Bank Balances	138.66	1,258.93		
	(d) Short-Term Loans and Advances	166.09	578.55		
	(e) Other Current Assets	139.21	78.51		
	TOTAL ASSETS	5,449.34	5,278.10		

For and on behalf of the Board of Directors of SHANMUGA HOSPITAL LIMITED

(formerly known as Shanmuga Hospital Private Limited)

Dr.Panneerselvam Prabu Sankar Executive Director & CEO DIN:08772888

Place:**Salem**Date: **12-11-2025** 

# (formerly known as Shanmuga Hospital Private Limited)

CIN: L85110TZ2020PLC033974

51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

## Statement of Unaudited Financial Results for the Half year ended as on September 30, 2025

(All amounts are in ₹. lakhs unless stated)

		For The Half - Year ended			For the year
Sr	Particulars	September 30, 2025	March 31, 2025	September 30, 2024	ended March 31, 2025
		Unaduited	Unaudited	Unaudited	Audited
I	Revenue From Operations	2,462.07	2,323.15	2,462.18	4,785.33
II	Other Income	9.94	2.72	20.63	23.35
III	Total Income (I+II)	2,472.01	2,325.87	2,482.81	4,808.67
IV	Expenses				
	Cost of Consumption	813.05	806.89	965.85	1,772.74
	Employee Benefits Expense	366.76	254.71	304.54	559.25
	Finance Costs	22.86	28.70	33.96	62.67
	Depreciation	170.89	110.06	105.74	215.80
	Other Expenses	828.12	880.37	749.10	1,629.48
	Total Expenses (IV)	2,201.68	2,080.73	2,159.20	4,239.94
V	Profit Before Exceptional and Extraordinary Items and Tax (III-IV)	270.33	245.14	323.60	568.74
VI	Exceptional Items	-	-	-	-
VII	Profit before extraordinary items and tax (V-VI)	270.33	245.14	323.60	568.74
VIII	Extraordinary items	_	_	_	_
	Prior Period Item	_	-	_	_
IX	Profit before tax (VII-VIII)	270.33	245.14	323.60	568.74
X	Tax Expense:				
	(1) Current Tax	41.67	53.45	80.39	133.84
	(2) Deferred Tax	27.53	9.85	3.92	13.77
	(3) Tax Adjustment for earlier years	-	0.46	-	0.46
XI	Profit ( Loss) for the period from continuning operations (IX-X)	201.13	181.38	239.29	420.67
XII	Profit ( Loss) for the period from discontinuning operations	_	-	-	-
XIII	Tax expenses of discontinuing operations	-	-	-	_
XIV	Profit ( Loss) for the period from discontinuning operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit/(Loss) For The Period (XI+XIV)	201.13	181.38	239.29	420.67
XVI	Earnings per equity share: (In ₹ Per share) * No.of Equity Shares in No's (in Lakhs)	136.13	136.13	97.95	136.13
	(1) Basic	1.48	1.64	2.44	4.03
	(2) Diluted	1.48	1.64	2.44	4.03

<sup>(\*)</sup> EPS is not annualized for the half year ended results. The EPS has been computed based on weighted average number of equity shares outstanding for the respective half year ended periods.

#### Notes on Standalone Financial Results:

- The above results which are published in accordance with Regulations 33 of SEBI (Listing Obligations & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 12, 2025. The financial results have been prepared in accordance with the Accounting Standards ("AS") as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 by the Ministry of Corporate Affairs and amendments thereof.
- As per Ministry of Corporate Affairs Notification dated February 16, 2015, Companies whose securities are listed on SME Exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.
- 3 The Company had issued 38,18,000 equity shares of ₹10 each at a premium of ₹44 per share by way of Initial Public Offer (IPO) and got listed on the SME Platform of BSE Limited on 21st February, 2025. Accordingly, these unaudited financial results for the half year ended September 30, 2025, are drawn in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

#### **Details of Utilization of IPO Proceeds:**

Rs.In Lakhs

Sr. No.	Object of issue	Amount disclosed in the Offer Document	Amount Unutilised as ar March 31,2025	Total Utilised up to September 30, 2025 *	Total Unutilised as at September 30,2025
1	Capital Expenditure	1,452.50	1,115.50	1,452.50	Nil
2	Issue Related Expenses	225.94	-	225.94	Nil
3	General Corporate Purposes	383.28	-	383.28	Nil
Grand Total		2,061.72	1,115.50	2,061.72	Nil

<sup>\*</sup> The opening unutilised IPO proceeds of as on April 01, 2025 was ₹1,115.50 lakhs and the same was fully utilised during the first half year Apr 2025 to Sep 2025 towards the object of issue.

- 4 The figures for the corresponding previous period have been regrouped / reclassified wherever necessary.
- The balance appearing under the Trade Payables Loans and Advances, Other Current Liabilities are subjected to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.
- There were no Investor Compliants pending received during the period under review
- 7 The Company operates only in one business segment Hospital and Healthcare Services hence, segment reporting is not applicable.
- 8 There were no exceptional and Extra- Ordinary items for the reporting period

For and on behalf of the Board of Directors of SHANMUGA HOSPITAL LIMITED

(formerly known as Shanmuga Hospital Private Limited)

Dr.Panneerselvam Prabu Sankar Executive Director & CEO DIN:08772888

Place:**Salem**Date: **12-11-2025** 

#### (formerly known as Shanmuga Hospital Private Limited) CIN: L85110TZ2020PLC033974

51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

Statement of Cash Flow For The Half-Year Ended September 30, 2025

(All amounts are in ₹. lakhs unless stated)

		_ `	. iakiis uiliess stateu)
		For the Half Year	For the Year ended
	Particulars	ended	March 31,2025
		September 30,2025	, , , , , , , , , , , , , , , , , , ,
	CACH ELOWS FROM OBERATING ACTIVITIES		
A	CASH FLOWS FROM OPERATING ACTIVITIES		
	Net Profit Before Tax	270.33	568.74
	Adjustments for:		
	Depreciation	170.89	215.80
	Gratuity Expenses	5.31	7.13
	Gratuity Paid	(17.07)	-
	Provision For Gratuity	-	_
	Interest Expenses	18.67	55.90
	Profit from sale of Investments		
	Dividend income	(0.05)	(0.06)
	Interest Income	(9.36)	(6.90)
	Operating Profit before working capital changes:	438.73	840.60
	Adjustments for changes in working capital:	430.73	040.00
		(0.00)	(02.00)
	(Increase)/Decrease in Inventories	(9.00)	(93.80)
	(Increase)/Decrease in Trade Receivables	175.34	(99.90)
	(Increase)/Decrease in Short term Loans & Advances(including other bank balances)	1,532.45	(1,666.55)
	(Increase)/Decrease in Other Current assets	(60.70)	140.58
	Increase/(Decrease) in Trade payables	49.55	(126.49)
	Increase/(Decrease)in Other Current Liabilities	(72.13)	37.90
	Cash generated from operations	2,054.25	(967.67)
	Less: Income Taxes Paid	(41.67)	(296.06)
	NET CASH FROM OPERATING ACTIVITES (A)	2,012.58	(1,263.72)
В	CASH FLOWS FROM INVESTING ACTIVITIES		
	Interest Received	9.36	6.90
	Profit from sale of Investments		
	Dividend income	0.05	0.06
	Purchase of Property, Plant and Equipment	(1,869.53)	(440.22)
	(Increase)/Decrease in Non-Current Investments	-	(0.25)
	(Increase)/Decrease in Other Non Current Assets	(110.98)	(14.79)
	NET CASH USED IN INVESTING ACTIVITIES (B)	(1,971.11)	(448.29)
C	CASH FLOWS FROM FINANCING ACTIVITIES		
	Interest paid	(18.67)	(55.90)
	(Repayment) of Long Term Borrowings	` - ′	′
	Proceeds/(Repayment) in Short Term Borrowings	(23.09)	(140.42)
	Proceeds from issue of equity shares less issue costs	(23.07)	1,835.78
	NET CASH USED IN FINANCING ACTIVITIES (C)	(41.76)	1,639.46
	The Chair Cold in Francisco ACTIVITES (C)	(41.70)	1,007.40
D	NET INCREASE IN CASH AND CASH EQUIVALENT (A+B+C)	(0.29)	(72.56)
	Opening Cash and Cash Equivalents	137.36	209.92
	CLOSING CASH AND CASH EQUIVALENT	137.07	137.36

#### Notes to Cash & Bank Balances:

Particulars	For the Half Year ended September 30,2025	For the Year ended March 31,2025
Cash & Bank balances comprise of		
a. Cash and cash equivalent		
Cash in Hand	66.98	39.02
Balance with Banks in Current Account	70.09	98.34
Subtotal (a)	137.07	137.36
b. Other Bank Balance with Scheduled Bank		
Balance with Banks in Deposit Account (having maturity more than 3 months but remaining maturity less than 12	1.59	1,121.58
Subtotal (b)	1.59	1,121.58
TOTAL(a) + (b)	138.66	1,258.93

- Notes:

  (i) The Cash flow statement is prepared as per AS 3 "Cash flow statement" where balance with banks in Deposit Account not treated as part of Cash and cash e
  (ii) Figures in brackets are outflows / deductions.
- (iii) The above Cash Flow Statement is prepared under the Indirect Method as set out in the Accounting Standards (AS-3) Statement of Cash Flows.

For and on behalf of the Board of Directors of SHANMUGA HOSPITAL LIMITED (formerly known as Shanmuga Hospital Private